Novartis Case Review
The Supreme Court’s Novartis judgment clarified Section 3d and its application to pharmaceutical patents in India. It emphasised the need for enhanced therapeutic efficacy and outlined critical standards…
Section 3(d)
32 articles
Abbott’s HIV Drug Patent “Not an Invention”
The Indian Patent Office has rejected Abbott’s application for an HIV drug patent, finding no inventive step in the claimed composition. This decision highlights the robust scrutiny applied…
Once an Intermediate, Always an Intermediate
This post examines the exclusion of patentability for new uses of known intermediates under Section 3d of the Indian Patents Act. It discusses the statutory language, its implications…
Patentability of New Form, Use or Property – Section 3(d)
Section 3(d) of the Indian Patents Act limits patentability for new forms or uses of known substances unless enhanced efficacy is proven. The Novartis case illustrates how courts…
Patentability and Section 3(d), History of Patent Law in India, Patentability of Imatinib Masylate in Beta Crystalline Form – Novartis Case Abridged by Dr. Kalyan C. Kankanala
This abridged Novartis case by Dr. Kalyan C. Kankanala explains the patentability requirements under Section 3(d) of Indian patent law. It provides a structured analysis of the legal…
Government Bats for US trained Patent Examiners
The Indian government’s plan to engage US trained patent examiners has sparked debate over efficiency and policy direction in the patent office. This post analyses the benefits, concerns,…
Pfizer Patent on Known Substance: A Section 3(d) Analysis
This post examines Pfizer’s patent application on a known substance and the Indian Patent Office’s refusal in light of Section 3d and the Novartis decision. It discusses whether…
Pfizer falls prey to Section 3(d)
This post analyses the Indian Patent Office’s rejection of Pfizer’s Tofacitinib patent under Section 3(d). The decision addresses issues of novelty, inventive step, and the requirement for evidence…
Roche loses again
The Indian Patent Office has revoked Roche’s Valganciclovir patent, emphasizing Section 3d and public interest. This decision strengthens access to medicines in India and curbs evergreening by pharmaceutical…
‘Killead’s Patent Application Killed by the Indian Patent Office!
Gilead’s patent for Sofosbuvir was rejected by the Indian Patent Office on grounds of insufficient therapeutic efficacy. This landmark decision enables wider access to affordable generic Hepatitis C…